The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

Acute Pulmonary Embolism Clinical Trial

Official title:

The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06192199
• Other study ID #: NFEC-2023-501
• Status: Recruiting
• Start date: January 1, 2024
• Est. completion date: December 1, 2026

Study information

• Verified date: January 2024
• Source: Nanfang Hospital, Southern Medical University
• Contact: Xintong Huang
• Phone: 8619355230761
• Email: 1556807596[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmonary embolism group and non pulmonary embolism group. 1. Collect relevant data, including gender, age, primary disease, CTPA imaging and reports, BNP, troponin, electrocardiogram, cardiac ultrasound, PT, APTT, TT, fibrinogen, D-dimer, etc., and analyze demographic data, pulmonary embolism risk grading, APTT/fibrinogen ratio, and determine their cut-off values through statistical analysis of the two groups. 2. Follow up on the APTT/fibrinogen ratio after anticoagulation treatment and bleeding in the pulmonary embolism group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 800
• Est. completion date: December 1, 2026
• Est. primary completion date: December 1, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntary signing of informed consent form;

2. When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender;

3. From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination.

Exclusion Criteria:

1. Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction;

2. Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation;

3. Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement;

4. Patients deemed unsuitable for participation in this study by the researchers.

Related Conditions & MeSH terms

• Acute Pulmonary Embolism
• Embolism
• Pulmonary Embolism

Intervention

Diagnostic Test:
• 2018 edition of the Guidelines for Diagnosis
According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group

Locations

Country	Name	City	State
China	Nanfang hospital of Southern Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Nanfang Hospital, Southern Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cutoff value of APTT/FIB between patients with and without acute pulmonary embolism		2024.01-2026.12